Eagle Pharmaceuticals (NASDAQ:EGRX) Coverage Initiated by Analysts at StockNews.com

StockNews.com started coverage on shares of Eagle Pharmaceuticals (NASDAQ:EGRX) in a research report released on Sunday morning. The brokerage issued a hold rating on the specialty pharmaceutical company’s stock.

Eagle Pharmaceuticals Price Performance

Shares of EGRX opened at $5.60 on Friday. Eagle Pharmaceuticals has a 1-year low of $3.21 and a 1-year high of $23.52. The firm has a market capitalization of $72.73 million, a PE ratio of 4.75 and a beta of 0.45. The company’s fifty day moving average price is $4.20 and its 200-day moving average price is $4.92.

Institutional Investors Weigh In On Eagle Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in the business. Price T Rowe Associates Inc. MD purchased a new stake in Eagle Pharmaceuticals in the first quarter valued at $83,000. Vanguard Group Inc. boosted its holdings in Eagle Pharmaceuticals by 0.4% in the first quarter. Vanguard Group Inc. now owns 640,754 shares of the specialty pharmaceutical company’s stock valued at $3,358,000 after purchasing an additional 2,630 shares during the last quarter. Headlands Technologies LLC raised its position in shares of Eagle Pharmaceuticals by 75.7% in the first quarter. Headlands Technologies LLC now owns 6,641 shares of the specialty pharmaceutical company’s stock worth $35,000 after acquiring an additional 2,861 shares during the period. DGS Capital Management LLC raised its position in shares of Eagle Pharmaceuticals by 442.5% in the first quarter. DGS Capital Management LLC now owns 61,944 shares of the specialty pharmaceutical company’s stock worth $325,000 after acquiring an additional 50,525 shares during the period. Finally, Los Angeles Capital Management LLC raised its position in shares of Eagle Pharmaceuticals by 110.1% in the first quarter. Los Angeles Capital Management LLC now owns 191,732 shares of the specialty pharmaceutical company’s stock worth $1,005,000 after acquiring an additional 100,470 shares during the period. 85.36% of the stock is owned by hedge funds and other institutional investors.

Eagle Pharmaceuticals Company Profile

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma.